(Q37724256)

22 August 2017

1 reference

title

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma (English)

1 reference

22 August 2017

Andrew X Zhu

1

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

Expert Opinion on Investigational Drugs

22 August 2017

published in

1 reference

22 August 2017

volume

19

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

663-672

1 reference

Global cancer statistics, 2002

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Expression of vascular endothelial growth factor in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Regulation and targets of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Expression and biosynthetic variation of the epidermal growth factor receptor in human hepatocellular carcinoma-derived cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543781003767426

10.1517/13543781003767426

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference